Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
Immunotherapy
; 14(12): 915-925, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1892545
ABSTRACT
Patients with cancer have a higher risk of severe COVID-19, and expert consensus advocates for COVID-19 vaccination in this population. Some cases of autoimmune hepatitis have been described after the administration of COVID-19 vaccine in the people in apparently good health. Immune checkpoint inhibitors (ICIs) are responsible for a wide spectrum of immune-related adverse events (irAEs). This article reports a case of hepatitis and colitis in a 52-year-old woman who was undergoing immunotherapy and was HBV positive 10 days after receiving the first Pfizer-BioNTech COVID-19 vaccine dose. Because both ICIs and the COVID-19 vaccines stimulate the immune response, the authors hypothesize that these vaccines may increase the incidence of irAEs during ICI treatment. There is a complex interplay between the immune-mediated reaction triggered by the vaccination and PD-L1 co-administration.
Patients with cancer have a higher risk of severe COVID-19, and expert consensus advocates for COVID-19 vaccination in this population. Some reports have described autoimmune hepatitis after the administration of COVID-19 vaccine. It is difficult, however, to establish a causal relationship between COVID-19 vaccination and autoimmune hepatitis. This article reports a case of hepatitis and colitis in a 52-year-old woman with lung cancer who was undergoing immunotherapy and was was found to be HBV positive 10 days after her first Pfizer-BioNTech COVID-19 vaccine dose. Because both immunotherapy and COVID-19 vaccines stimulate the immune response, the authors hypothesize that these vaccines may increase the incidence of immune-related side effects.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antineoplastic Agents, Immunological
/
COVID-19 Vaccines
/
COVID-19
/
Hepatitis
/
Neoplasms
Type of study:
Case report
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Immunotherapy
Journal subject:
Allergy and Immunology
/
Therapeutics
Year:
2022
Document Type:
Article
Affiliation country:
Imt-2021-0342
Similar
MEDLINE
...
LILACS
LIS